GLTO

#11856
Damora Therapeutics, Inc. Common Stock
28.69 USD
-0.76%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
28.69
28.69
Yıllık Aralık
2.01
38.33
Günlük Değişim
-0.76%
Aylık Değişim
-6.00%
6 aylık değişim
+917.38%
Yıllık Değişim
+613.68%
Önceki Kapanış
28.91
Open
28.69
Bid
Ask
Low
28.69
High
28.69
Hacim
10
Open full chart

Financials

Overview Rapor Statistics
Quarterly Annual
  • Market Capitalization 1.59 B
  • Employee 7
  • Founded 2011
  • CEO Hans T. Schambye
  • Website www.damoratx.com
  • Headquarter Delaware, United States
  • FIGI BBG00XMLGWC5
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-5.78
Price to sales ratio
28.96

Galecto Inc

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark. The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.

Haberler